Experimental HCV Drugs
Experimental HCV Drugs
Merck and Roche to Collaborate on Combination Regimens for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 16 December 2011 00:00
- Written by Press Release
Merck this week announced a collaboration with Roche to evaluate combination regimens for chronic hepatitis C virus (HCV) infection containing Merck's approved HCV protease inhibitor boceprevir (Victrelis) and Roche's experimental HCV polymerase inhibitor mericitabine (formerly RO5024048 and RG7128).
Two New Nucleotide HCV Polymerase Inhibitors Enter Clinical Trials
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 December 2011 00:00
- Written by Press Release
A pair of hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitors, ALS-2200 and ALS-2158, are now entering Phase 1 human trials, according to a recent announcement.
AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
- Written by Liz Highleyman
The hepatitis C virus (
HCV) NS3/4A protease inhibitor danoprevir (formerly RG7128) plus pegylated interferon/ribavirin produced high cure rates and many patients were eligible for shorter therapy, according to findings presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
New Hepatitis C NS5A Inhibitor ACH-2928 Shows Potent Antiviral Activity
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
- Written by Press Release
Achillion's novel once-daily hepatitis C virus (HCV) NS5A inhibitor ACH-2928 was well-tolerated and lowered viral load by more than 3.6 log in a 3-day monotherapy study, the company announced this week. These findings suggest ACH-2928 may be a promising candidate for inclusion in future oral direct-acting antiviral regimens.
HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study
- Details
- Category: HCV Treatment
- Published on Tuesday, 06 December 2011 00:00
- Written by Inhibitex
Biopharmaceutical company Inhibitex last week announced early safety and efficacy data from a 7-day Phase 1b study evaluating its investigational once-daily hepatitis C virus (HCV) polymerase inhibitor INX-189 plus ribavirin in an interferon-free oral regimen. This study looked at treatment-naive patients with difficult-to-treat HCV genotype 1; the company now plans to test higher doses of INX-189 and combinations with other direct-acting antivirals, and to include people with genotypes 2 or 3.
More Articles...
- AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- Companies to Evaluate Daclatasvir plus TMC435 for Hepatitis C
- AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- Novel Compound Dissolves HIV on Contact, also Kills Hepatitis C Virus
Web Design and Development by